Ball Kristine M sold 2,500 shares of Oruka Therapeutics, Inc. at $106.05 for −$265k on Nov 12, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$265,130Shares × reported price
Shares traded
2,500Common Stock
Price per share
$106.05Reported price. Read footnotes for ranges.
% of reported position traded
92.59%This security and ownership context
Holdings after
200Direct
Trade date
Nov 12, 2026Sell
Filed
Nov 13, 2026, 7:59 PM ET2-day reporting delay
Accession
0000907654-26-000115Code S · Transaction 401425
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 2,700 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Sell1,196$102.10−$122,107.65Trade 401421
Nov 12, 2026Sell1,300$103.09−$134,021.16Trade 401422
Nov 12, 2026Sell2,039$104.16−$212,386.73Trade 401423
Nov 12, 2026Sell10,765$105.31−$1,133,706.29Trade 401424
Nov 12, 2026Sell200$106.99−$21,397Trade 401426
Nov 12, 2026Option exercise18,000$0.00$0Trade 401427
Nov 12, 2026Option exercise18,000$6.84$123,120Trade 401420
8 transaction rows in this filing. Joint filers share the same rows.

ORKA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ORKA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 21, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −26%1w ago −8.9%1d ago +1.7%
Returns since7d30d90d180d1y

Footnotes in full

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.62 to $102.61, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.66 to $103.65, inclusive. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.69 to $104.65, inclusive. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.76 to $105.75, inclusive. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.76 to $106.46, inclusive. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.97 to $107.00, inclusive. F8: The option vests as to 1/4 of the underlying shares on May 7, 2025 and as to 1/48 of the underlying shares monthly from May 7, 2025.